Oppenheimer Asset Management Inc. Acquires 2,675 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Oppenheimer Asset Management Inc. grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,473 shares of the company's stock after buying an additional 2,675 shares during the quarter. Oppenheimer Asset Management Inc. owned 0.15% of Medpace worth $15,179,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Signaturefd LLC raised its stake in shares of Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company's stock valued at $230,000 after purchasing an additional 26 shares in the last quarter. Wealth Alliance lifted its holdings in Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company's stock worth $399,000 after buying an additional 27 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of Medpace by 0.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company's stock worth $1,787,000 after acquiring an additional 32 shares in the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in shares of Medpace by 1.7% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company's stock valued at $793,000 after acquiring an additional 39 shares during the last quarter. Finally, Journey Advisory Group LLC raised its position in shares of Medpace by 1.9% during the 2nd quarter. Journey Advisory Group LLC now owns 2,390 shares of the company's stock valued at $984,000 after acquiring an additional 44 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of research reports. TD Cowen decreased their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and cut their target price for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Guggenheim reduced their price objective on shares of Medpace from $464.00 to $432.00 and set a "buy" rating for the company in a research report on Wednesday, July 24th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Medpace from $395.00 to $336.00 and set a "hold" rating on the stock in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $380.00.

Medpace Price Performance

Shares of NASDAQ MEDP traded down $27.10 during trading hours on Thursday, hitting $334.84. 343,330 shares of the stock were exchanged, compared to its average volume of 277,879. The firm has a market capitalization of $10.41 billion, a P/E ratio of 31.08, a P/E/G ratio of 2.00 and a beta of 1.37. The company's 50 day moving average is $342.27 and its 200 day moving average is $376.61. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company posted $2.22 earnings per share. Research analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.